366 related articles for article (PubMed ID: 25608155)
21. [The correlation between metabolic parameters in (18)F-FDG PET-CT and solid and micropapillary histological subtypes in lung adenocarcinoma].
Guo Y; Yao ZM; Chen M; Chen CX
Zhonghua Zhong Liu Za Zhi; 2022 Jun; 44(6):555-561. PubMed ID: 35754230
[No Abstract] [Full Text] [Related]
22. Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes.
Hong SJ; Kim TJ; Choi YW; Park JS; Chung JH; Lee KW
Eur Radiol; 2016 Oct; 26(10):3660-8. PubMed ID: 26787602
[TBL] [Abstract][Full Text] [Related]
23. Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma.
Jeong CJ; Lee HY; Han J; Jeong JY; Lee KS; Choi YL; Choi JY
Clin Nucl Med; 2015 Jan; 40(1):e34-9. PubMed ID: 25243942
[TBL] [Abstract][Full Text] [Related]
24. Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma.
Shi Z; Zheng X; Shi R; Song C; Yang R; Zhang Q; Wang X; Lu J; Yu Y; Liu Q; Jiang T
Sci Rep; 2017 Mar; 7(1):364. PubMed ID: 28336963
[TBL] [Abstract][Full Text] [Related]
25. Imaging characteristics of stage I non-small cell lung cancer on CT and FDG-PET: relationship with epidermal growth factor receptor protein expression status and survival.
Lee Y; Lee HJ; Kim YT; Kang CH; Goo JM; Park CM; Paeng JC; Chung DH; Jeon YK
Korean J Radiol; 2013; 14(2):375-83. PubMed ID: 23483676
[TBL] [Abstract][Full Text] [Related]
26. Lung adenocarcinoma: Assessment of epidermal growth factor receptor mutation status based on extended models of diffusion-weighted image.
Yuan M; Pu XH; Xu XQ; Zhang YD; Zhong Y; Li H; Wu JF; Yu TF
J Magn Reson Imaging; 2017 Jul; 46(1):281-289. PubMed ID: 28054731
[TBL] [Abstract][Full Text] [Related]
27. Value of
Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
29. Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma.
Hsu JS; Huang MS; Chen CY; Liu GC; Liu TC; Chong IW; Chou SH; Yang CJ
J Thorac Imaging; 2014 Nov; 29(6):357-63. PubMed ID: 25303964
[TBL] [Abstract][Full Text] [Related]
30. Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation.
Choi CM; Kim MY; Hwang HJ; Lee JB; Kim WS
Radiology; 2015 Apr; 275(1):272-9. PubMed ID: 25575117
[TBL] [Abstract][Full Text] [Related]
31. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?
Han G; Bi J; Tan W; Wei X; Wang X; Ying X; Guo X; Zhou X; Hu D; Zhen W
Oncotarget; 2016 Aug; 7(35):56998-57010. PubMed ID: 27486770
[TBL] [Abstract][Full Text] [Related]
32. CT imaging-based histogram features for prediction of EGFR mutation status of bone metastases in patients with primary lung adenocarcinoma.
Shen TX; Liu L; Li WH; Fu P; Xu K; Jiang YQ; Pan F; Guo Y; Zhang MC
Cancer Imaging; 2019 Jun; 19(1):34. PubMed ID: 31174617
[TBL] [Abstract][Full Text] [Related]
33. EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma.
Tanaka K; Hida T; Oya Y; Oguri T; Yoshida T; Shimizu J; Horio Y; Hata A; Kaji R; Fujita S; Sekido Y; Kodaira T; Kokubo M; Katakami N; Yatabe Y
J Thorac Oncol; 2015 Dec; 10(12):1720-5. PubMed ID: 26743855
[TBL] [Abstract][Full Text] [Related]
34. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients.
Lee SM; Bae SK; Jung SJ; Kim CK
Clin Nucl Med; 2015 Dec; 40(12):950-8. PubMed ID: 26359571
[TBL] [Abstract][Full Text] [Related]
35. Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive?
Usuda K; Sagawa M; Motono N; Ueno M; Tanaka M; Machida Y; Matoba M; Taniguchi M; Tonami H; Ueda Y; Sakuma T
Asian Pac J Cancer Prev; 2014; 15(2):657-62. PubMed ID: 24568474
[TBL] [Abstract][Full Text] [Related]
36. Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma.
Fujimoto D; Tomii K; Otoshi T; Kawamura T; Tamai K; Takeshita J; Tanaka K; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Hata A; Tachikawa R; Otsuka K; Hamakawa H; Katakami N; Takahashi Y; Imai Y
Lung Cancer; 2013 May; 80(2):159-64. PubMed ID: 23419507
[TBL] [Abstract][Full Text] [Related]
37. Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.
Takahashi R; Hirata H; Tachibana I; Shimosegawa E; Inoue A; Nagatomo I; Takeda Y; Kida H; Goya S; Kijima T; Yoshida M; Kumagai T; Kumanogoh A; Okumura M; Hatazawa J; Kawase I
Clin Cancer Res; 2012 Jan; 18(1):220-8. PubMed ID: 22019513
[TBL] [Abstract][Full Text] [Related]
38. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
[TBL] [Abstract][Full Text] [Related]
39. FDG PET texture indices as imaging biomarkers for epidermal growth factor receptor mutation status in lung adenocarcinoma.
Ishimura M; Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Murota M; Kanaji N; Nishiyama Y
Sci Rep; 2023 Apr; 13(1):6742. PubMed ID: 37185611
[TBL] [Abstract][Full Text] [Related]
40. [Potential value of FDG PET-CT in predicting occult lymph node metastasis in clinical stage ⅠA lung adenocarcinoma].
Lyu L; Liu Y; Wang XY; Zhang ZK; Tao XL; Yang L; Wu N
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):441-447. PubMed ID: 31216830
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
